Interaction between tacrolimus and lansoprazole, but not rabeprazole in living-donor liver transplant patients with defects of CYP2C19 and CYP3A5

Keiko Hosohata, Satohiro Masuda, Yasuhiro Ogura, Fumitaka Oike, Yasutsugu Takada, Toshiya Katsura, Shinji Uemoto, Ken Ichi Inui

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

We report different effects of administration of proton pump inhibitors on tacrolimus blood concentration in two living-donor liver transplant patients. In case 1, a 51-year-old man with liver cirrhosis due to hepatitis C virus underwent living-donor liver transplantation, and tacrolimus was orally administered. Omeprazole (40 mg/day) was introduced intravenously between postoperative days 5 and 6, and oral lansoprazole (30 mg/day) was introduced from day 6, leading to an increase in the concentration/dose ratio of tacrolimus from day 10. In case 2, a 41-year-old living-donor liver transplant woman received tacrolimus, and co-administered with omeprazole (40 mg/day) intravenously during 7 days immediately after surgery. During this period, trough concentration of tacrolimus was high, but the concentration/dose ratio of tacrolimus was gradually decreasing with time. Switched to rabeprazole (10 mg/day) orally on the postoperative 8th day, the concentration/dose ratio of tacrolimus remained low, indicating little drug-drug interaction between tacrolimus and rabeprazole. In both cases, the genotypes of CYP2C19 and CYP3A5 were defective both in the graft liver and in the native intestine. A drug-drug interaction between rabeprazole and tacrolimus was not observed in this case study presented, suggesting that this combination could be safely used in tacrolimus therapy after liver transplantation.

Original languageEnglish
Pages (from-to)134-138
Number of pages5
JournalDrug metabolism and pharmacokinetics
Volume23
Issue number2
DOIs
Publication statusPublished - Jan 1 2008
Externally publishedYes

Fingerprint

Rabeprazole
Lansoprazole
Cytochrome P-450 CYP3A
Living Donors
Tacrolimus
Transplants
Liver
Omeprazole
Drug Interactions
Liver Transplantation
Cytochrome P-450 CYP2C19
Proton Pump Inhibitors
Hepacivirus
Liver Cirrhosis
Pharmaceutical Preparations
Intestines
Genotype

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science
  • Pharmacology (medical)

Cite this

Interaction between tacrolimus and lansoprazole, but not rabeprazole in living-donor liver transplant patients with defects of CYP2C19 and CYP3A5. / Hosohata, Keiko; Masuda, Satohiro; Ogura, Yasuhiro; Oike, Fumitaka; Takada, Yasutsugu; Katsura, Toshiya; Uemoto, Shinji; Inui, Ken Ichi.

In: Drug metabolism and pharmacokinetics, Vol. 23, No. 2, 01.01.2008, p. 134-138.

Research output: Contribution to journalArticle

Hosohata, Keiko ; Masuda, Satohiro ; Ogura, Yasuhiro ; Oike, Fumitaka ; Takada, Yasutsugu ; Katsura, Toshiya ; Uemoto, Shinji ; Inui, Ken Ichi. / Interaction between tacrolimus and lansoprazole, but not rabeprazole in living-donor liver transplant patients with defects of CYP2C19 and CYP3A5. In: Drug metabolism and pharmacokinetics. 2008 ; Vol. 23, No. 2. pp. 134-138.
@article{c6080d9b87b149cfbf171c321e18bd94,
title = "Interaction between tacrolimus and lansoprazole, but not rabeprazole in living-donor liver transplant patients with defects of CYP2C19 and CYP3A5",
abstract = "We report different effects of administration of proton pump inhibitors on tacrolimus blood concentration in two living-donor liver transplant patients. In case 1, a 51-year-old man with liver cirrhosis due to hepatitis C virus underwent living-donor liver transplantation, and tacrolimus was orally administered. Omeprazole (40 mg/day) was introduced intravenously between postoperative days 5 and 6, and oral lansoprazole (30 mg/day) was introduced from day 6, leading to an increase in the concentration/dose ratio of tacrolimus from day 10. In case 2, a 41-year-old living-donor liver transplant woman received tacrolimus, and co-administered with omeprazole (40 mg/day) intravenously during 7 days immediately after surgery. During this period, trough concentration of tacrolimus was high, but the concentration/dose ratio of tacrolimus was gradually decreasing with time. Switched to rabeprazole (10 mg/day) orally on the postoperative 8th day, the concentration/dose ratio of tacrolimus remained low, indicating little drug-drug interaction between tacrolimus and rabeprazole. In both cases, the genotypes of CYP2C19 and CYP3A5 were defective both in the graft liver and in the native intestine. A drug-drug interaction between rabeprazole and tacrolimus was not observed in this case study presented, suggesting that this combination could be safely used in tacrolimus therapy after liver transplantation.",
author = "Keiko Hosohata and Satohiro Masuda and Yasuhiro Ogura and Fumitaka Oike and Yasutsugu Takada and Toshiya Katsura and Shinji Uemoto and Inui, {Ken Ichi}",
year = "2008",
month = "1",
day = "1",
doi = "10.2133/dmpk.23.134",
language = "English",
volume = "23",
pages = "134--138",
journal = "Drug Metabolism and Pharmacokinetics",
issn = "1347-4367",
publisher = "Japanese Society for the Study of Xenobiotics",
number = "2",

}

TY - JOUR

T1 - Interaction between tacrolimus and lansoprazole, but not rabeprazole in living-donor liver transplant patients with defects of CYP2C19 and CYP3A5

AU - Hosohata, Keiko

AU - Masuda, Satohiro

AU - Ogura, Yasuhiro

AU - Oike, Fumitaka

AU - Takada, Yasutsugu

AU - Katsura, Toshiya

AU - Uemoto, Shinji

AU - Inui, Ken Ichi

PY - 2008/1/1

Y1 - 2008/1/1

N2 - We report different effects of administration of proton pump inhibitors on tacrolimus blood concentration in two living-donor liver transplant patients. In case 1, a 51-year-old man with liver cirrhosis due to hepatitis C virus underwent living-donor liver transplantation, and tacrolimus was orally administered. Omeprazole (40 mg/day) was introduced intravenously between postoperative days 5 and 6, and oral lansoprazole (30 mg/day) was introduced from day 6, leading to an increase in the concentration/dose ratio of tacrolimus from day 10. In case 2, a 41-year-old living-donor liver transplant woman received tacrolimus, and co-administered with omeprazole (40 mg/day) intravenously during 7 days immediately after surgery. During this period, trough concentration of tacrolimus was high, but the concentration/dose ratio of tacrolimus was gradually decreasing with time. Switched to rabeprazole (10 mg/day) orally on the postoperative 8th day, the concentration/dose ratio of tacrolimus remained low, indicating little drug-drug interaction between tacrolimus and rabeprazole. In both cases, the genotypes of CYP2C19 and CYP3A5 were defective both in the graft liver and in the native intestine. A drug-drug interaction between rabeprazole and tacrolimus was not observed in this case study presented, suggesting that this combination could be safely used in tacrolimus therapy after liver transplantation.

AB - We report different effects of administration of proton pump inhibitors on tacrolimus blood concentration in two living-donor liver transplant patients. In case 1, a 51-year-old man with liver cirrhosis due to hepatitis C virus underwent living-donor liver transplantation, and tacrolimus was orally administered. Omeprazole (40 mg/day) was introduced intravenously between postoperative days 5 and 6, and oral lansoprazole (30 mg/day) was introduced from day 6, leading to an increase in the concentration/dose ratio of tacrolimus from day 10. In case 2, a 41-year-old living-donor liver transplant woman received tacrolimus, and co-administered with omeprazole (40 mg/day) intravenously during 7 days immediately after surgery. During this period, trough concentration of tacrolimus was high, but the concentration/dose ratio of tacrolimus was gradually decreasing with time. Switched to rabeprazole (10 mg/day) orally on the postoperative 8th day, the concentration/dose ratio of tacrolimus remained low, indicating little drug-drug interaction between tacrolimus and rabeprazole. In both cases, the genotypes of CYP2C19 and CYP3A5 were defective both in the graft liver and in the native intestine. A drug-drug interaction between rabeprazole and tacrolimus was not observed in this case study presented, suggesting that this combination could be safely used in tacrolimus therapy after liver transplantation.

UR - http://www.scopus.com/inward/record.url?scp=43749101127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43749101127&partnerID=8YFLogxK

U2 - 10.2133/dmpk.23.134

DO - 10.2133/dmpk.23.134

M3 - Article

C2 - 18445994

AN - SCOPUS:43749101127

VL - 23

SP - 134

EP - 138

JO - Drug Metabolism and Pharmacokinetics

JF - Drug Metabolism and Pharmacokinetics

SN - 1347-4367

IS - 2

ER -